Plaquenil and Primary sequestrum - a phase IV clinical study of FDA data

Summary:

Primary sequestrum is reported as a side effect among people who take Plaquenil (hydroxychloroquine sulfate), especially for people who are female, 50-59 old, also take Zometa, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Primary sequestrum when taking Plaquenil. It is created by eHealthMe based on reports of 88,348 people who have side effects when taking Plaquenil from the FDA, and is updated regularly.

What is Plaquenil?

Plaquenil has active ingredients of hydroxychloroquine sulfate. It is often used in systemic lupus erythematosus. eHealthMe is studying from 91,018 Plaquenil users. Check the latest studies of Plaquenil.

What is Primary sequestrum?

Primary sequestrum (piece of dead bone that has become separated during the process of necrosis from normal/sound bone) is found to be associated with 598 drugs and 330 conditions by eHealthMe. Check the latest studies of Primary sequestrum.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

88,348 people reported to have side effects when taking Plaquenil.
Among them, 53 people (0.06%) have Primary sequestrum.

Could Plaquenil cause Primary sequestrum?

Among these 53 people:

What is the gender of people who have Primary sequestrum when taking Plaquenil? *

female: 56.6 %
male: 43.4 %

What is the age of people who have Primary sequestrum when taking Plaquenil? *

What are other drugs people take besides Plaquenil? *

What are other side effects people have besides Primary sequestrum? *

Osteomyelitis (infection of bone): 49 people, 92.45%
Osteonecrosis Of Jaw (death of bone of jaw): 48 people, 90.57%
Joint Pain: 45 people, 84.91%
Stress And Anxiety: 42 people, 79.25%
Pain: 42 people, 79.25%
Fall: 39 people, 73.58%
Pneumonia: 33 people, 62.26%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 32 people, 60.38%
Rashes (redness): 31 people, 58.49%
Infection: 30 people, 56.60%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 27 people, 50.94%
Skin Ulcer: 12 people, 22.64%
Mouth Ulcers: 12 people, 22.64%
Neoplasm Malignant (cancer tumour): 7 people, 13.21%
Metastases To Bone (cancer spreads to bone): 7 people, 13.21%
Breast Cancer: 7 people, 13.21%
Insomnia (sleeplessness): 3 people, 5.66%
Osteoporosis (bones weak and more likely to break): 2 people, 3.77%
Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 1.89%
High Blood Pressure: 1 person, 1.89%

* Approximation only. Some reports may have incomplete information.

Do you take Plaquenil and have Primary sequestrum?

- Check whether Primary sequestrum is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Plaquenil:

Plaquenil (91,018 reports)

Browse all side effects of Plaquenil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Primary sequestrum:

Primary sequestrum (598 drugs)

Browse all the conditions that are associated with Primary sequestrum:

Primary sequestrum (330 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on hydroxychloroquine sulfate (the active ingredients of Plaquenil) and Plaquenil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.